Join the 'Varubi' group to help and get support from people like you.
Posted 30 Jun 2017 by Drugs.com
FRIDAY, June 30, 2017 – Your friends are excited to ride that monster roller coaster, but just looking at it makes you queasy. Is there anything you can do to quell your motion sickness so you can join in the fun? If you suffer from motion sickness, there are some ways to deal with it, one doctor says, though riding roller coasters isn't likely an activity you'll ever love. Motion sickness can occur in cars, on planes, boats, trains and amusement park rides, and even when sitting too close to a movie theater screen or using a virtual reality device. Motion sickness occurs when the brain gets mixed information. The brain combines input from the eyes with information from the parts of the body touching the ground, and then links that information with the vestibular system in the ears that controls balance. If these things don't match up, motion sickness can occur. "Some people can feel ... Read more
Related support groups: Nausea/Vomiting, Ativan, Lorazepam, Benadryl, Promethazine, Diphenhydramine, Zofran, Phenergan, Meclizine, Reglan, Ondansetron, Marinol, Dramamine, Metoclopramide, Motion Sickness, Compazine, Thorazine, Prochlorperazine, Scopolamine, Perphenazine
Posted 2 Sep 2015 by Drugs.com
September 2, 2015 – The U.S. Food and Drug Administration approved Varubi (rolapitant) to prevent delayed phase chemotherapy-induced nausea and vomiting (emesis). Varubi is approved in adults in combination with other drugs (antiemetic agents) that prevent nausea and vomiting associated with initial and repeat courses of vomit-inducing (emetogenic and highly emetogenic) cancer chemotherapy. Nausea and vomiting are common side effects experienced by cancer patients undergoing chemotherapy. Symptoms can persist for days after the chemotherapy drugs are administered. Nausea and vomiting that occurs from 24 hours to up to 120 hours after the start of chemotherapy is referred to as delayed phase nausea and vomiting, and it can result in serious health complications. Prolonged nausea and vomiting can lead to weight loss, dehydration and malnutrition in cancer patients leading to ... Read more
Posted 2 Sep 2015 by Drugs.com
WEDNESDAY, Sept. 2, 2015 – Varubi (rolapitant) has been approved by the U.S. Food and Drug Administration to treat nausea and vomiting among adults undergoing cancer chemotherapy. Nausea and vomiting are common side effects of chemotherapy that can persist for days after the drugs are given. Prolonged bouts of these reactions can lead to weight loss, dehydration and malnutrition, the agency said Wednesday in a news release. Varubi was evaluated by some 2,800 participants in three clinical trials, administered in combination with other anti-nausea drugs. The most common side effects included low white blood cell count, hiccups, loss of appetite and dizziness. The FDA said Varubi should not be taken by people who are taking the drug thioridazine, which is commonly prescribed to treat schizophrenia. Varubi is marketed by Tesaro Inc., based in Waltham, Mass. More information The FDA has ... Read more